XLR-11 4-Hydroxypentyl metabolite-D5

Description

 RESTRICTED PRODUCT 

Schedule 9 (S9) Licence required.

This product requires an Australian government issued permit to hold or possess.

A stable-labeled internal standard of the primary urinary metabolite of XLR-11, a popular third generation synthetic cannabinoid that purportedly can cause serious adverse health effects including kidney damage and stroke. XLR-11 is similar in structure to UR-144 and A-796,260, two compounds originally developed as pharmaceutical drug candidates due to their high affinity for the cannabinoid receptor CB2. For those synthetic cannabinoids currently controlled at the federal level, our certified solution standards of these substances are DEA-exempt, allowing laboratories to place orders without additional regulatory paperwork. For US customers, state specific regulatory requirements may apply.